These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27890855)

  • 1. Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.
    Cazzamalli S; Corso AD; Neri D
    J Control Release; 2017 Jan; 246():39-45. PubMed ID: 27890855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma.
    Cazzamalli S; Dal Corso A; Neri D
    Mol Cancer Ther; 2016 Dec; 15(12):2926-2935. PubMed ID: 27609641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
    Krall N; Pretto F; Mattarella M; Müller C; Neri D
    J Nucl Med; 2016 Jun; 57(6):943-9. PubMed ID: 26912427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Smart CA IX-Targeting and pH-Responsive Nano-Mixed Micelles for Delivery of FB15 with Superior Anti-Breast Cancer Efficacy.
    Liu X; Zhao J; Liu F; Xie Z; Lei X; Wang Z; Yang Z; Zhou Y; Tang G
    Int J Nanomedicine; 2024; 19():10247-10262. PubMed ID: 39403708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
    Cazzamalli S; Ziffels B; Widmayer F; Murer P; Pellegrini G; Pretto F; Wulhfard S; Neri D
    Clin Cancer Res; 2018 Aug; 24(15):3656-3667. PubMed ID: 29691298
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.
    Cazzamalli S; Dal Corso A; Widmayer F; Neri D
    J Am Chem Soc; 2018 Feb; 140(5):1617-1621. PubMed ID: 29342352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.
    Marks IS; Gardeen SS; Kurdziel SJ; Nicolaou ST; Woods JE; Kularatne SA; Low PS
    Mol Pharm; 2018 Jun; 15(6):2289-2296. PubMed ID: 29715036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Targeting with Small Molecule-Drug Conjugates (SMDCs) - Can They be Better than ADCs?
    Altmann KH
    Chimia (Aarau); 2018 Mar; 72(3):154-155. PubMed ID: 29631670
    [No Abstract]   [Full Text] [Related]  

  • 9. Acetazolamide-based [
    More KN; Lee JY; Kim DY; Cho NC; Pyo A; Yun M; Kim HS; Kim H; Ko K; Park JH; Chang DJ
    Bioorg Med Chem Lett; 2018 Mar; 28(5):915-921. PubMed ID: 29422388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.
    Gébleux R; Stringhini M; Casanova R; Soltermann A; Neri D
    Int J Cancer; 2017 Apr; 140(7):1670-1679. PubMed ID: 27943268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.
    Alsaab HO; Sau S; Alzhrani RM; Cheriyan VT; Polin LA; Vaishampayan U; Rishi AK; Iyer AK
    Biomaterials; 2018 Nov; 183():280-294. PubMed ID: 30179778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.
    Dal Corso A; Cazzamalli S; Gébleux R; Mattarella M; Neri D
    Bioconjug Chem; 2017 Jul; 28(7):1826-1833. PubMed ID: 28662334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma.
    Kleinendorst SC; Oosterwijk E; Molkenboer-Kuenen J; Frielink C; Franssen GM; Boreel DF; Tamborino G; Gloudemans M; Hendrikx M; Kroon D; Hillen J; Bussink J; Muselaers S; Mulders P; Konijnenberg MW; Wheatcroft MP; Twumasi-Boateng K; Heskamp S
    Theranostics; 2024; 14(9):3693-3707. PubMed ID: 38948062
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of carbonic anhydrase IX in glioblastoma multiforme.
    Amiri A; Le PU; Moquin A; Machkalyan G; Petrecca K; Gillard JW; Yoganathan N; Maysinger D
    Eur J Pharm Biopharm; 2016 Dec; 109():81-92. PubMed ID: 27702686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSMA-targeted small-molecule drug-conjugates with valine-citrulline and phosphoramidate cleavable linkers.
    Savoy EA; Olatunji FP; Fulton MD; Kesic BN; Herman JW; Romero O; Maniatopoulos M; Berkman CE
    Bioorg Med Chem Lett; 2024 Jan; 98():129573. PubMed ID: 38052377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.
    Ziffels B; Stringhini M; Probst P; Fugmann T; Sturm T; Neri D
    Mol Cancer Ther; 2019 Sep; 18(9):1544-1554. PubMed ID: 31213507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
    Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
    Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A CAIX Dual-Targeting Small-Molecule Probe for Noninvasive Imaging of ccRCC.
    He C; Liu F; Tao J; Wang Z; Liu J; Liu S; Xu X; Li L; Wang F; Yang X; Zhu H; Yang Z
    Mol Pharm; 2024 Jul; 21(7):3383-3394. PubMed ID: 38831541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting carbonic anhydrase IX with small organic ligands.
    Wichert M; Krall N
    Curr Opin Chem Biol; 2015 Jun; 26():48-54. PubMed ID: 25721398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
    BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.